US tourist dies after drinking hallucinogenic tea during ritual in Peru's Amazon forest
Ayahuasca, which can be fatal and cause irreversible damage, is a concoction traditionally used by Indigenous cultures in the Amazon for spiritual and healing rituals. Reports say the ceremony took place in a hostel in the Santa Maria de Ojeda community, which has become associated with 'spiritual tourism' in recent years.
According to hostel staff, Castranova failed to inform the ceremony organisers that he was taking antibiotics at the time he consumed the hallucinogenic brew.
Ayahuasca tourism has surged in recent years, with many retreats offering the Indigenous brew to visitors under the guidance of a shaman, with tourists often seeking it out as a remedy for depression.
Interestingly, ayahuasca is the same drug Prince Harry admitted to taking to help him cope with the death of his mother, Princess Diana. However, the US Embassy in Peru has explicitly warned American tourists against consuming traditional hallucinogens like ayahuasca.
'These dangerous substances are often marketed to travellers in Peru as ceremonial or spiritual cleansers. However, Ayahuasca is a psychoactive substance containing dimethyltryptamine (DMT), a strong hallucinogen that is illegal in the United States and many other countries,' the US Embassy's website.
Castranova's death comes a year after a British woman died at a Bolivian retreat known for its use of psychedelic substances. Maureen Rainford, a social worker, had booked a ten-day stay in October 2024 at the Ayahuasca and San Pedro Pisatahua Retreat. She collapsed during her stay and died about an hour later, despite CPR efforts.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
2 hours ago
- NDTV
US Beverage Brand Issues Urgent Recall Over Vodka-Filled Energy Drinks
American alcoholic beverage brand High Noon is recalling its energy drink cans due to a major labelling issue. The company has voluntarily recalled two lots of its High Noon Beach Variety 12-packs, according to a press release. The announcement came after some cans were filled with High Noon Vodka Seltzer and mislabelled as the non-alcoholic Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition. As a result, consuming the beverage in these cans may lead to accidental alcohol consumption. Reportedly, no illnesses or health incidents have been documented as of now. The mix-up happened after a packaging supplier mistakenly sent empty Celsius cans to High Noon, a brand that specialises in hard seltzer. The empty cans were filled with alcohol and then delivered to Florida, New York, Ohio, South Carolina, Virginia and Wisconsin between July 21 and 23. Also Read: Viral Video Shows Man Allegedly Drinking Alcohol In Delhi Metro. His Clarification... Only two lots of High Noon Beach Variety Packs have this labelling error – one with Lot Codes L CCC 17JL25 14:00 to L CCC 17JL25 23:59 and another with Lot Codes L CCC 18JL25 00:00 to L CCC 18JL25 03:00. Consumers are urged to discard the Celsius-labelled recalled cans. If they have already bought the recalled High Noon Beach Variety 12-packs, they may reach out to High Noon Consumer Relations about the next steps, including how to obtain a refund. "We are working with the FDA, retailers and distributors to proactively manage the recall to ensure the safety and well-being of our consumers. The states that may be impacted are: Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin,' said a representative for High Noon in a statement to The Independent. High Noon is a popular American hard seltzer brand known for its drinks made with real vodka or tequila and real fruit juice. It was launched in 2019 by E & J Gallo Winery, a prominent American wine and spirits company. It is one of the fastest-growing alcoholic seltzer brands in the US.
NDTV
7 hours ago
- NDTV
Trump's New Health Data Tracking System Raises Privacy Concerns
Washington: President Donald Trump has announced a plan for a new private health tracking system that will make it easier for patients to access their health records and monitor their wellness across health care systems and technologies. The system, however, is raising a host of privacy questions. The collaboration between the federal government and Big Tech would allow patients to more seamlessly track and share their medical records or data among doctors, hospital systems and health apps, the administration and participating companies say. Details of the system were announced Wednesday during a White House event dubbed "Making Health Technology Great Again." The system would be maintained by the federal government through the Centers for Medicare and Medicaid Services, pulling health data kept by Big Tech companies like Amazon, Google and Apple as well as major health companies like hospital system Cleveland Clinic and insurer UnitedHealth Group. Patients will need to opt in to have their medical records and data shared, which CMS says will be kept secure. Once a patient is in the system, their information could be shared across apps or health systems that have joined the initiative. So, for example, the Apple Health app on your iPhone that tracks your daily step count or your sleep could access lab results from your doctor's office. Putting that information together, the Trump administration says, will offer a fuller picture of your health. Apps and AI technology could also help people make better choices at the grocery store or identify patterns in their day-to-day life that might be affecting their health, said US Health and Human Services Secretary Robert F Kennedy Jr during Wednesday's White House event. "Now if you have your medical records, you can get personalised advice," Kennedy said. Currently, there's no unified database where a person's health data and medical records are kept. Each health system stores, shares and releases patients' records in different ways, with some even still faxing records to doctors working in other offices or hospitals. Some health networks have their own apps or websites that allow patients to look up their records online. The US Department of Health and Human Services says that 60 companies have signed on to work with the system and that they have pledged to "deliver results to the American people in the first quarter of 2026." The Trump administration, however, made a similar proposal back in 2018 that never fully came to fruition. Patient advocates and ethicists say many may worry about how their health information - something Americans have long carefully guarded - could be used in ways that they don't want or expect. "There are enormous ethical and legal concerns," said Lawrence Gostin, a Georgetown University law professor who specializes in public health. "Patients across America should be very worried that their medical records are going to be used in ways that harm them and their families." Also, digital privacy advocates say they are skeptical that patients will be able to count on their data being stored securely. "This scheme is an open door for the further use and monetization of sensitive and personal health information," said Jeffrey Chester at the Center for Digital Democracy.
Time of India
10 hours ago
- Time of India
Trump's tariff move on India may backfire, pharma industry leaders say
The Indian pharmaceutical industry has hit back strongly at the recent tariff announcement by U.S. President Donald Trump , calling it a move that could hurt the American healthcare system more than India's economy. Reacting to the U.S. decision to impose a 25 per cent tariff on Indian goods, Dilip Kumar, Chairman of Medical Tourism at the Chamber of Commerce, told that the move aimed at damaging the Indian economy. However, he expressed confidence that it would not succeed. Explore courses from Top Institutes in Please select course: Select a Course Category Design Thinking Product Management Project Management others Operations Management Leadership Healthcare Finance Data Analytics CXO Technology MBA Cybersecurity PGDM Data Science MCA Data Science healthcare Public Policy Others Management Skills you'll gain: Duration: 25 Weeks IIM Kozhikode CERT-IIMK PCP DTIM Async India Starts on undefined Get Details "He is trying to kill the market of the Indian economy, but it is not going to happen," Kumar said. "We are exporters, especially of medical equipment, pharmaceuticals, and disposables, which mostly come from India. The American market is dependent upon Indian and Chinese markets." Live Events You Might Also Like: Indian IT sector not directly hit by US tariffs, yet ripple effects could be substantial: EY India Kumar emphasized that the cost of treatment and medical procedures in the U.S. will increase as a result of this move, directly affecting American citizens. "India won't be impacted, as we will go by the route of exporting to European countries. We can survive in the toughest times and bounce back," he added. Echoing similar concerns, Namit Joshi, Chairman of Pharmexcil, highlighted the critical role India plays in the global pharmaceutical supply chain . He said that India supplies nearly 47 per cent of the U.S.'s pharmaceutical needs, especially in the generic drugs segment. "India has long been a cornerstone of the global supply chain for affordable, high-quality medicines, particularly in the generic drug market, where it supplies nearly 47 per cent of the U.S.'s pharmaceutical needs. Indian pharmaceutical companies play a vital role in ensuring the affordability and availability of essential medications, including life-saving oncology drugs, antibiotics, and chronic disease treatments," Joshi said. He warned that any disruption to this supply chain would lead to shortages and rising prices in the U.S. "The immediate consequences of these tariffs will likely result in increased costs for essential drugs, the long-term impact will be even more severe," he said. Joshi added that the U.S. market , which relies heavily on India for Active Pharmaceutical Ingredients (APIs) and low-cost generics, would struggle to find alternatives. "Efforts to shift pharmaceutical manufacturing and API production to other countries or within the U.S. will take at least 3-5 years to establish meaningful capacity." Industry experts believe the tariff move is a miscalculation that may damage the very healthcare system it aims to protect. However, clarity has to come whether the new 25 per cent tariffs will apply to India's pharmaceutical sector, as in an earlier announcement of April, President Trump had exempted the pharma sector from tariffs. Economic Times WhatsApp channel )
